IPSEN (OTCMKTS:IPSEY) Sees Unusually-High Trading Volume – Time to Buy?

IPSEN (OTCMKTS:IPSEY) saw unusually-strong trading volume on Thursday. 16,248 shares traded hands during trading, an increase of 762% from the previous session’s volume of 1,885 shares. The stock last traded at $40.15 and had previously closed at $39.89.

Analyst Upgrades and Downgrades

A number of brokerages have commented on IPSEY. Barclays upgraded IPSEN from a “strong sell” rating to a “hold” rating in a research note on Thursday, September 17th. Jefferies Financial Group lowered shares of IPSEN from a “hold” rating to a “moderate sell” rating in a research report on Sunday, August 2nd. Finally, HC Wainwright reissued a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold”.

IPSEN Trading Up 0.7%

The business has a 50-day simple moving average of $45.42 and a 200-day simple moving average of $46.34.

IPSEN Company Profile

Ipsen SA is a France-based biopharmaceutical company focused on the discovery, development and commercialization of medicines in specialty care. Its principal therapeutic areas are oncology, rare diseases and neuroscience, with an emphasis on treatments for conditions that often have limited therapeutic options.

The company’s portfolio includes Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected movement disorders and aesthetic applications, and cancer treatments such as Cabometyx and Onivyde.